LARIMAR THERAPEUTICS
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
LARIMAR THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2005-01-01
Address:
Bala Cynwyd, Pennsylvania, United States
Country:
United States
Website Url:
http://www.larimartx.com
Total Employee:
11+
Status:
Active
Contact:
844-511-9056
Email Addresses:
[email protected]
Total Funding:
250.18 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Adagene
Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies.
Aerovate Therapeutics
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
Avistone Pharmaceuticals
Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.
Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics.
Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Inhibrx
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Magenta Therapeutics
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
OSE Immunotherapeutics
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing.
Pluri
Pluri is at the forefront of a biotech revolution that promotes global well-being and sustainability.
Potenza Therapeutics
Potenza Therapeutics is a preclinical-stage biotechnology company focused on building a portfolio of oncology programs.
LENZ Therapeutics
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Sensei Biotherapeutics
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Viracta Therapeutics
Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-12-18 | Chondrial Therapeutics | Chondrial Therapeutics acquired by Larimar Therapeutics | N/A |
Investors List
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Post-IPO Equity - Larimar Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Larimar Therapeutics
Vivo Capital
Vivo Capital investment in Post-IPO Equity - Larimar Therapeutics
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Larimar Therapeutics
Verition Fund Management
Verition Fund Management investment in Post-IPO Equity - Larimar Therapeutics
Adage Capital Management
Adage Capital Management investment in Post-IPO Equity - Larimar Therapeutics
Deerfield
Deerfield investment in Post-IPO Equity - Larimar Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - Larimar Therapeutics
MidCap Financial
MidCap Financial investment in Debt Financing - Larimar Therapeutics
Venrock
Venrock investment in Series E - Larimar Therapeutics
Official Site Inspections
http://www.larimartx.com Semrush global rank: 4.19 M Semrush visits lastest month: 2.82 K
- Host name: 74.226.109.208.host.secureserver.net
- IP address: 208.109.226.74
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Larimar Therapeutics"
Company Overview – Larimar Therapeutics
Company Overview. Larimar Therapeutics, based in the Philadelphia area, is committed to discovering and developing treatments for complex rare diseases, with an initial focus on …See details»
Leadership – Larimar Therapeutics
© 2024 Larimar Therapeutics, Inc. All rights reserved. LARIMAR and LARIMAR THERAPEUTICS are trademarks of Larimar Therapeutics, Inc.See details»
Larimar Therapeutics - Crunchbase Company Profile & Funding
Organization. Larimar Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Larimar Therapeutics is a clinical …See details»
Larimar Therapeutics Inc. | LinkedIn
Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is ...See details»
Larimar Therapeutics, Inc. (LRMR)
See the company profile for Larimar Therapeutics, Inc. (LRMR) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Larimar Therapeutics Announces Formation of Scientific Advisory …
Oct 13, 2020 The RDI is the first Clinical Center of Excellence designated by the National Organization for Rare Diseases (NORD) ... please visit: https://larimartx.com. Investor Contact: …See details»
Larimar Therapeutics - Overview, News & Similar companies
May 30, 2024 Larimar Therapeutics contact info: Phone number: (844) 511-9056 Website: www.larimartx.com What does Larimar Therapeutics do? Larimar Therapeutics, Inc. (Nasdaq: …See details»
About Larimar – Larimar Therapeutics
© 2024 Larimar Therapeutics, Inc. All rights reserved. LARIMAR and LARIMAR THERAPEUTICS are trademarks of Larimar Therapeutics, Inc.See details»
Larimar Therapeutics Selected by FDA to Participate in START Pilot ...
May 30, 2024 For more information, please visit: https://larimartx.com. Forward-Looking Statements This press release contains forward-looking statements that are based on …See details»
Larimar Therapeutics Reports Third Quarter 2023 Operating and …
Nov 14, 2023 For more information, please visit: https://larimartx.com. Forward-Looking Statements This press release contains forward-looking statements that are based on …See details»
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 ...
Mar 14, 2024 Larimar Therapeutics. Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in tissue …See details»
Leadership – Larimar Therapeutics
Gopi Shankar, PhD, MBA, FAAPS, joined Larimar Therapeutics in February, 2023 as Chief Development Officer bringing over 20 years of experience leading the development of novel …See details»
Larimar Therapeutics Presents Additional Data from Phase 1 …
BALA CYNWYD, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing …See details»
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 …
Larimar Therapeutics. Nomlabofusp was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse eventsSee details»
Contact Us – Larimar Therapeutics
Larimar Therapeutics. Three Bala Plaza East Suite 506 Bala Cynwyd, PA 19004 844-511-9056See details»
Larimar Therapeutics, Inc. (LRMR) - Yahoo Finance
Find the latest Larimar Therapeutics, Inc. (LRMR) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
November 2021 - investors.larimartx.com
3 Investment Highlights Clinical-stage biotechnology company with a novel protein replacement therapy platform Focused on addressing unmet needs in Friedreich's ataxia (FA) and other …See details»
Board of Directors – Larimar Therapeutics
© 2024 Larimar Therapeutics, Inc. All rights reserved. LARIMAR and LARIMAR THERAPEUTICS are trademarks of Larimar Therapeutics, Inc.See details»
Larimar Therapeutics Reports Third Quarter 2021 Operating and …
Sep 30, 2021 BALA CYNWYD, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company …See details»